DATE: October 11th, 2019
LOCATION: Education Resource Center Auditorium
TIME: 12:00 – 12:15 Pick Up Lunch
12:15 - 1:15 Department Update/Grand Rounds Lecture
TITLE: “HCV Infection in 2019: Are we on the path to elimination?”
Speaker: Susanna Naggie, MD, MHS

For CME and MOC go to: https://med.virginia.edu/cme/learning/uvarss/medgrmoc/

LEARNING OBJECTIVES:

1) Discuss HCV epidemiology and elimination goals
2) Discuss HCV treatment including in unique populations
3) Discuss challenges to elimination and how to address them
4) Discuss SVR benefits

QUESTIONS:
1. WHO HCV elimination goals for 2030 include:
   a) 65% mortality reduction
   b) 90% incidence reduction
   c) 70% treatment coverage
   d) 75% diagnosis coverage
2. Currently the US is failing to achieve which WHO HCV elimination goal?
   a) Mortality reduction
   b) Incidence reduction
   c) Treatment coverage
   d) Diagnosis coverage
3. Which HCV drug target combination is not currently recommended in US for initial or retreatment HCV therapy?
   a) NS5A/NS5B combination
   b) NS3/NS5A combination
   c) NS3/NS5B combination
   d) NS3/NS5A/NS5B combination
4) True or FALSE – The current recommended length of therapy for HCV infection is 8-12 weeks.
5) True or False – Patients with cirrhosis continue to have the same rates of HCC diagnosis after SVR as those patients with cirrhosis not achieving SVR.

DISCLOSURES: Dr. Naggie has received research support from AbbVie, Gilead Sciences, Inc, Tacere; serves as scientific advisor for Vir and BioMarin; serves on event adjudication committee for PRA and FHI360. (Updated 10/01/2019)